Sentiment-Signal
15,4
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 29.12.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
| 09.12.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 14.08.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | rth by specific reference in such filing. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; |
| 07.07.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ciated with, the actions described above. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; |
| 26.09.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
| 19.01.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departures of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; C |
| 14.11.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
| 05.05.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | el Diem, M.D., to Chief Financial Officer. Item 5.02 Departure of Directors or Principal Officers; Election of Directo |
| 17.04.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Office |
Stammdaten
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
Unternehmen & Branche
| Name | Century Therapeutics, Inc. |
|---|---|
| Ticker | IPSC |
| CIK | 0001850119 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 190,0 Mio. USD |
| Beta | 1,67 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 109,164,000 | -9,580,000 | -0.14 | 223,704,000 | 158,936,000 |
| 2025-09-30 | 10-Q | 109,164,000 | -34,422,000 | -0.40 | 244,717,000 | 176,348,000 |
| 2025-06-30 | 10-Q | 109,164,000 | -32,541,000 | -0.38 | 284,692,000 | 209,898,000 |
| 2025-03-31 | 10-Q | 109,164,000 | 76,560,000 | 0.89 | 315,609,000 | 240,439,000 |
| 2024-12-31 | 10-K | 6,589,000 | -126,566,000 | -1.61 | 353,216,000 | 161,362,000 |
| 2024-09-30 | 10-Q | 791,000 | -31,226,000 | -0.37 | 388,617,000 | 195,686,000 |
| 2024-06-30 | 10-Q | 771,000 | -31,207,000 | -0.38 | 416,446,000 | 222,104,000 |
| 2024-03-31 | 10-Q | 855,000 | -28,062,000 | -0.45 | 348,507,000 | 177,883,000 |
| 2023-12-31 | 10-K | 2,235,000 | -136,673,000 | -2.30 | 360,691,000 | 184,750,000 |
| 2023-09-30 | 10-Q | 148,000 | -32,720,000 | -0.55 | 397,551,000 | 219,230,000 |
| 2023-06-30 | 10-Q | 99,000 | -33,291,000 | -0.56 | 417,159,000 | 247,571,000 |
| 2023-03-31 | 10-Q | 1,720,000 | -31,264,000 | -0.53 | 456,228,000 | 277,175,000 |
| 2022-12-31 | 10-K | 5,199,000 | -130,932,000 | -2.96 | 486,544,000 | 302,738,000 |
| 2022-09-30 | 10-Q | 2,224,000 | -30,749,000 | -0.53 | 511,751,000 | 330,205,000 |
| 2022-06-30 | 10-Q | 1,396,000 | -30,988,000 | -0.54 | 532,584,000 | 357,952,000 |
| 2022-03-31 | 10-Q | 1,058,000 | -37,513,000 | -0.66 | 550,308,000 | 386,664,000 |
| 2021-12-31 | 10-K | -95,824,000 | -2.96 | 437,375,000 | 396,238,000 | |
| 2021-09-30 | 10-Q | -26,009,000 | -0.48 | 469,725,000 | 422,988,000 | |
| 2021-06-30 | 10-Q | -23,273,000 | -1.93 | 495,630,000 | 447,597,000 | |
| 2021-03-31 | 10-Q | -18,348,000 | -2.39 | -91,557,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-12 | Russotti Gregory | Officer, See Remarks | Open Market Sale | -10,076 | 2.55 | -25,683.72 | -337,3% | |
| 2026-03-12 | Carr Douglas | Officer, SVP Finance & Operations | Open Market Sale | -7,043 | 2.55 | -17,952.61 | -235,8% | |
| 2026-03-09 | Russotti Gregory | Officer, See Remarks | Open Market Sale | -479 | 2.54 | -1,214.74 | -16,0% | |
| 2026-03-09 | Carr Douglas | Officer, SVP Finance & Operations | Open Market Sale | -247 | 2.54 | -626.39 | -8,2% | |
| 2026-02-03 | Carr Douglas | Officer, SVP Finance & Operations | Open Market Sale | -323 | 1.82 | -588.51 | -7,7% | |
| 2025-12-22 | Cowan Chad | Officer, Chief Scientific Officer | Open Market Purchase | 58,060 | 0.85 | 49,252.30 | +646,9% | |
| 2025-12-12 | Pfeiffenberger Brent | Director, Officer, President and CEO | Open Market Purchase | 52,000 | 0.58 | 30,352.40 | +398,6% | |
| 2025-12-08 | Carr Douglas | Officer, SVP Finance & Operations | Open Market Sale | -257 | 0.53 | -136.72 | -1,8% | |
| 2025-12-08 | Russotti Gregory | Officer, See Remarks | Open Market Sale | -526 | 0.53 | -279.83 | -3,7% | |
| 2025-11-20 | Cowan Chad | Officer, Chief Scientific Officer | Open Market Sale | -5,462 | 0.50 | -2,736.46 | -35,9% | |
| 2025-11-19 | Pfeiffenberger Brent | Director, Officer, President and CEO | Open Market Purchase | 35,000 | 0.50 | 17,328.50 | +227,6% | |
| 2025-11-17 | Pfeiffenberger Brent | Director, Officer, President and CEO | Open Market Sale | -32,456 | 0.45 | -14,735.02 | -193,5% | |
| 2025-11-03 | Carr Douglas | Officer, SVP Finance & Operations | Open Market Sale | -292 | 0.59 | -171.11 | -2,2% | |
| 2025-09-08 | Russotti Gregory | Officer, See Remarks | Open Market Sale | -539 | 0.50 | -269.50 | -3,5% | |
| 2025-09-08 | Pfeiffenberger Brent | Director, Officer, President and CEO | Open Market Sale | -488 | 0.50 | -244.00 | -3,2% | |
| 2025-09-08 | Carr Douglas | Officer, SVP Finance & Operations | Open Market Sale | -263 | 0.50 | -131.50 | -1,7% | |
| 2025-08-04 | Carr Douglas | Officer, SVP Finance & Operations | Open Market Sale | -296 | 0.53 | -158.06 | -2,1% | |
| 2025-06-09 | Carr Douglas | Officer, SVP Finance & Operations | Open Market Sale | -4,904 | 0.62 | -3,050.29 | -40,1% | |
| 2025-06-09 | Farid Adrienne | Officer, Chief Operations Officer | Open Market Sale | -552 | 0.62 | -343.34 | -4,5% | |
| 2025-06-09 | Russotti Gregory | Officer, See Remarks | Open Market Sale | -526 | 0.62 | -327.17 | -4,3% | |
| 2025-06-09 | Pfeiffenberger Brent | Director, Officer, President and CEO | Open Market Sale | -475 | 0.62 | -295.45 | -3,9% | |
| 2025-05-16 | Pfeiffenberger Brent | Director, Officer, President and CEO | Open Market Sale | -29,552 | 0.55 | -16,135.39 | -211,9% | |
| 2025-05-05 | Farid Adrienne | Officer, Chief Operations Officer | Open Market Sale | -1,024 | 0.55 | -563.20 | -7,4% | |
| 2025-05-05 | Carr Douglas | Officer, SVP Finance & Operations | Open Market Sale | -295 | 0.55 | -162.25 | -2,1% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.